Business
Argent BioPharma Expands Pipeline with Promising Drug CimetrA®
Argent BioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company addressing unmet medical needs by developing innovative treatments for central nervous system and immune-related disorders through neuro-immune modulation and advanced nano-medicine technology, is pleased to announce positive Phase IIb clinical trial results for CimetrA®, a novel anti-inflammatory treatment. The study confirmed CimetrA®'s strong safety profile and demonstrated faster recovery times in COV
About this update from Argent Biopharma Ltd
[{"type":"text","content":"PERTH, Australia, March 16, 2025 /PRNewswire/ -- Argent BioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company addressing unmet medical needs by developing innovative treatments for central nervous system and immune-related disorders through neuro-immune modulation and advanced nano-medicine technology, is pleased to announce positive Phase IIb clinical trial results for CimetrA®, a novel anti-inflammatory treatment. The study confirmed CimetrA®'s strong safety profile and demonstrated faster recovery times in COVID-19 patients.","length":573,"tagName":"p"},{"type":"text","content":"Key Findings:","length":13,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"No drug-related adverse events, reinforcing CimetrA®'s safety.","length":66,"tagName":"p"}]},{"val":[{"type":"text","content":"Faster clinical improvement versus placebo, measured by the WHO Ordinal Scale.","length":83,"tagName":"p"}]},{"val":[{"type":"text","content":"Reduced inflammation, with significant modulation of key inflammatory markers (IL-6, IL-1β, TNF-α, and more).","length":109,"tagName":"p"}]},{"val":[{"type":"text","content":"Improved quality of life trends observed in CimetrA®-treated patients.","length":70,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":328,"olType":false},{"type":"text","content":"CEO Roby Zomer stated:"These promising results highlight CimetrA®'s potential as a breakthrough treatment for inflammatory diseases beyond COVID-19. We are excited about its future clinical development."","length":223,"tagName":"p"},{"type":"text","content":"With these findings, Argent BioPharma continues to advance innovative therapies. One such therapy, CannEpil®, is an oral mucosal solution with a high-CBD, low-THC formulation. It is designed to reduce seizure frequency and severity while minimizing psychoactive effects. After years of clinical development, CannEpil® is making waves in the UK as part of a movement to transform severe epilepsy treatment. This further reinforces Argent BioPharma's commitment to addressing global health challenges.","length":508,"tagName":"p"},{"type":"text","content":"For further information, please contact:","length":40,"tagName":"p"},{"type":"text","content":"Argent BioPharmaRoby ZomerCEO & Managing Director+61 8...